Patients Who Receive 131 I-MIBG

Brain and Nervous System Clinical Trial

Official title:
An Observational Study of Patients With Recurrent Progressive or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Who Receive 131 I- MIBG

Status Withdrawn

Clinical Trial Summary

This study is for patients who have have neuroblastoma, pheochromocytoma, or paraganglioma that has come back (relapsed) after treatment or has not gotten better (refractory) with standard treatment. The purpose of this study is to evaluate quality of life and response rate to 131 I-MIBG treatment.

Clinical Trial Description

This is an observational, single institution study designed to determine the benefit of 131I-MIBG therapy in subjects with refractory, relapsed or progressive neuroblastoma, malignant pheochromocytoma or paraganglioma, or other neuroendocrine tumors. Response rate, time to progression, and quality of life changes will be evaluated. ;

Study Design

Related Conditions & MeSH terms

Brain and Nervous System

Clinical Trial Details

NCT number	NCT04770831
Study type	Observational
Source	Wake Forest University Health Sciences
Contact
Status	Withdrawn
Phase
Start date	March 10, 2021
Completion date	December 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01778764` - Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases
Active, not recruiting	`NCT04022980` - Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma	Phase 1
Completed	`NCT00251797` - A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors	Phase 1
Recruiting	`NCT05474378` - B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme	Phase 1
Completed	`NCT03076255` - Head and Neck Maskless Immobilization Device in Immobilizing Patients With Head and Neck Cancer or Intracranial Tumors Undergoing Radiation Therapy	N/A